Progenics Pharmaceuticals (Pro 140) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Progenics Pharmaceuticals (Pro 140) General Information

Description

Monoclonal antibody HIV viral-entry inhibitor drug in the United States.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Corporate Office
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Progenics Pharmaceuticals (Pro 140) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Progenics Pharmaceuticals (Pro 140)‘s full profile, request access.

Request a free trial

Progenics Pharmaceuticals (Pro 140) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Progenics Pharmaceuticals (Pro 140)‘s full profile, request access.

Request a free trial

Progenics Pharmaceuticals (Pro 140) FAQs

  • Where is Progenics Pharmaceuticals (Pro 140) headquartered?

    Progenics Pharmaceuticals (Pro 140) is headquartered in .

  • What industry is Progenics Pharmaceuticals (Pro 140) in?

    Progenics Pharmaceuticals (Pro 140)’s primary industry is Buildings and Property.

  • Is Progenics Pharmaceuticals (Pro 140) a private or public company?

    Progenics Pharmaceuticals (Pro 140) is a Private company.

  • What is the current valuation of Progenics Pharmaceuticals (Pro 140)?

    The current valuation of Progenics Pharmaceuticals (Pro 140) is .

  • What is Progenics Pharmaceuticals (Pro 140)’s current revenue?

    The current revenue for Progenics Pharmaceuticals (Pro 140) is .

  • Who are Progenics Pharmaceuticals (Pro 140)’s investors?

    Progenics Pharmaceuticals has invested in Progenics Pharmaceuticals (Pro 140).

  • When was Progenics Pharmaceuticals (Pro 140) acquired?

    Progenics Pharmaceuticals (Pro 140) was acquired on 30-Jul-2012.

  • Who acquired Progenics Pharmaceuticals (Pro 140)?

    Progenics Pharmaceuticals (Pro 140) was acquired by Cytodyn.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process